Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.
Cranial magnetic resonance imaging (MRI) is widely used to monitor disease activity in clinical trials in multiple sclerosis (MS). The purpose of this study is to examine lesion burden as determined from hypointense regions on postcontrast T1-weighted scans (or black holes), and lesion burden on conventional T2-weighted scans, from a cohort of secondary progressive MS patients who participated in a placebo-controlled, randomized, double-blind cross-over trial assessing the therapeutic efficacy of cladribine. T2 lesion volumes and black hole volumes are approximately normal distributed when log-transformed, and are highly correlated (adjusted R2 = 0.63). Changes in clinical scores could be predicted with a reasonable degree of precision from baseline scores and changes in T2 lesion volumes (adjusted R2 values 0.52-0.7). Stratification schemes for clinical trials should include the acute proportion of the disease (enhancing T1 lesions), degree of permanent damage (black holes), and T2 lesion volume.
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, Calif. 92037, USA. hp@scripps.edu
H P
HP
Adams
S
S
Wagner
D F
DF
Sobel
L S
LS
Slivka
J C
JC
Sipe
J S
JS
Romine
E
E
Beutler
J A
JA
Koziol
D000328:Adult; D017338:Cladribine / Q000627:therapeutic use*; D004185:Disability Evaluation; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D009460:Neurologic Examination; D010919:Placebos; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D010919:Placebos; D017338:Cladribine